Core disease areas
Spinal muscular atrophy (SMA)
SMA is a rare and devastating genetic disease caused by a lack of a functional survival motor neuron 1 (SMN1) gene, resulting in the rapid and irreversible loss of motor neurons.
Multiple sclerosis (MS)
Multiple sclerosis (MS) is a chronic disorder of the central nervous system that disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss. Approximately 2.3 million people worldwide are affected by MS, of which 3 to 5% are estimated to be children.
Migraine is a serious and distinct neurological disease affecting 1 billion people worldwide, and impacting women three times more than men. Migraine involves recurrent attacks of moderate-to-severe head pain associated with nausea, vomiting and sensitivity to light, sound and odors.
In neuroscience, “an inflection point in knowledge and technology”
Bob Baloh’s interest in drug development’s potential was piqued early in graduate school. At the time, he was working in a lab making growth factors that had potential applications as therapeutics for patients with Parkinson’s disease.
Fighting MS through innovation
Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).
Latest neuroscience news
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
Novartis publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis
Clinical trials and pipeline projects
Find neuroscience-related clinical trials and learn more about the projects in development around neuroscience.
Learn more about the other Novartis core therapeutic areas